Get the Stockscreener App
1.648
0.02%
0.008
Pmv Pharmaceuticals Inc stock is traded at $1.648, with a volume of 69,385.
It is up +0.02% in the last 24 hours and up +7.21% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
See More
Previous Close:
$1.64
Open:
$1.63
24h Volume:
69,385
Relative Volume:
0.35
Market Cap:
$84.23M
Revenue:
-
Net Income/Loss:
$-68.96M
P/E Ratio:
-1.011
EPS:
-1.63
Net Cash Flow:
$-56.62M
1W Performance:
-0.59%
1M Performance:
+7.21%
6M Performance:
-17.57%
1Y Performance:
-14.12%
1-Day Range:
$1.62
$1.66
1-Week Range:
$1.59
$1.66
52-Week Range:
$1.40
$3.47
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6664
Address
ONE RESEARCH WAY, PRINCETON
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors - OncLive
US Penny Stocks To Consider In October 2024 - Simply Wall St
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial - GlobeNewswire
SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
SG Americas Securities LLC Grows Stake in Stellantis (NYSE:STLA) - Defense World
ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML - OncLive
Envestnet Asset Management Inc. Sells 2,501 Shares of Juniper Networks, Inc. (NYSE:JNPR) - Defense World
Point72 Asia Singapore Pte. Ltd. Takes $101,000 Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
Pawan Singh sharing his grief with Mata Rani, asking questions from his mind, Pawan Singh sharing his grief with Mata Rani, asking questions from his mind - AnyTV News
Small Cap Stocks: Plexus, Parkmead, Proton Motor - The Armchair Trader
Stock market news: PC Jeweller shares hit 5% upper circuit- Check Details - MSN
Vanguard Personalized Indexing Management LLC Increases Position in PDD Holdings Inc. (NASDAQ:PDD) - Defense World
2 ASX shares I can’t ignore: PME and SOL - Rask Media
40% women with PCOD may get diabetes: Experts - The Times of India
Parvin Dabas, Pro Panja League Co-Founder, In ICU After Road Accident - Pratidin Time
Agency News | ⚡Pro Panja League Co-Founder and Actor Parvin Dabas Admitted to ICU Following Car Accident - LatestLY
Should PME shares be on your watchlist? - Rask Media
Power Mech Shares Gain on Securing Orders Worth Rs 865 Crore - EquityPandit
Power Mech rises on Rs 865-cr order win from Vedanta's subsidiary - Business Standard
Bowers & Wilkins Launches Px7 S2e “Ruby Red” and Px8 “Dark Forest” - HYPEBEAST
Bowers & Wilkins adds two new colors to PX7 S2e & PX8 headphones - Gstyle magazine
PMV Pharmaceuticals executive sells over $10k in company stock By Investing.com - Investing.com Canada
PMV Pharmaceuticals CFO sells over $4,300 in company stock By Investing.com - Investing.com Canada
PMV Pharmaceuticals executive sells over $10k in company stock - Investing.com India
Insider Selling: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells 7,218 Shares of Stock - MarketBeat
PMV Pharmaceuticals CFO sells over $4,300 in company stock - Investing.com India
Wharton San Diego Presents: The Future of Biotechnology in San Diego - Procopio
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL - OncLive
Closing Figures: PMV Pharmaceuticals Inc (PMVP)’s Negative Finish at 1.58, Down -1.25 - The Dwinnex
Assenagon Asset Management S.A. Has $401,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Envestnet Portfolio Solutions Inc. Buys 5,351 Shares of MBIA Inc. (NYSE:MBI) - Defense World
Gene and Cell Therapy: Shaping the Future of Medicine - OncLive
Assenagon Asset Management S.A. Boosts Stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
PMV Pharmaceuticals, Inc. to Post Q3 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecasts (NASDAQ:PMVP) - MarketBeat
PMV Pharmaceuticals' (PMVP) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - StockTitan
PMVP (PMV Pharmaceuticals) EPS (Basic) : $-0.97 (TTM As of Jun. 2024) - GuruFocus.com
PMVP (PMV Pharmaceuticals) Purchase Of Investment : $-162.36 Mil (TTM As of Jun. 2024) - GuruFocus.com
PMVP (PMV Pharmaceuticals) GF Value Rank : 0 (As of Aug. 19, 2024) - GuruFocus.com
PMVP (PMV Pharmaceuticals) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
Vanguard Group Inc. Purchases 46,804 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer - OncLive
Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis - OncLive
Panasonic (OTCMKTS:PCRFY) Stock Price Crosses Below Fifty Day Moving Average of $9.36 - Defense World
PMV Pharmaceuticals Initiates Strategic Lease Termination - TipRanks
PMV Pharmaceuticals Reports Second Quarter 2024 Financial - GlobeNewswire
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial - StockTitan
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
| ORBIMED ADVISORS LLC | 10% Owner |
Nov 22 '23 |
Sale |
2.23 |
87,786 |
195,763 |
0 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):